Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I Shapiro

Showing results (901-910 of 1,171) with videos related to

Pageof 118
Sort By:
ESMO Open|May 13, 2025
A phase I/II study of the safety and efficacy of telaglenastat (CB-839) in combination with nivolumab in patients with metastatic melanoma, renal cell carcinoma, and non-small-cell lung cancerM A Gouda, M H Voss, H Tawbi, et al.
NPJ Breast Cancer|April 26, 2025
MUC1-C dependency in drug resistant HR+/HER2- breast cancer identifies a new target for antibody-drug conjugate treatmentAyako Nakashoji, Atrayee Bhattacharya, Hiroki Ozawa, et al.
Oncogene|February 22, 2007
The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272Y Minami, T Shimamura, K Shah, et al.
JAMA Network Open|October 18, 2022
Diagnostic Accuracy of a Bacterial and Viral Biomarker Point-of-Care Test in the Outpatient SettingNathan I Shapiro, Michael R Filbin, Peter C Hou, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 12, 2013
Co-clinical trials demonstrate superiority of crizotinib to chemotherapy in ALK-rearranged non-small cell lung cancer and predict strategies to overcome resistanceZhao Chen, Esra Akbay, Oliver Mikse, et al.
Acta Physiologica (Oxford, England)|March 22, 2021
The Na/K-ATPase α1/Src interaction regulates metabolic reserve and Western diet intoleranceLaura C Kutz, Xiaoyu Cui, Jeffrey X Xie, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 29, 2012
A phase I first-in-human trial of bardoxolone methyl in patients with advanced solid tumors and lymphomasDavid S Hong, Razelle Kurzrock, Jeffrey G Supko, et al.
Journal of the American Society of Nephrology : JASN|April 14, 2006
Non-contrast-enhanced computerized tomography and analgesic-related kidney disease: report of the national analgesic nephropathy studyWilliam L Henrich, Richard L Clark, Judith P Kelly, et al.
Molecular Cancer Research : MCR|November 29, 2022
MUC1-C Dictates PBRM1-Mediated Chronic Induction of Interferon Signaling, DNA Damage Resistance, and Immunosuppression in Triple-Negative Breast CancerNami Yamashita, Yoshihiro Morimoto, Atsushi Fushimi, et al.
Cancer|April 26, 2017
Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus: Results of a phase 2 studyEytan Ben-Ami, Constance M Barysauskas, Sarah Solomon, et al.
Pageof 118

Showing results (901-910 of 1,171) with videos related to

Sort By:
Pageof 118
ESMO Open|May 13, 2025
A phase I/II study of the safety and efficacy of telaglenastat (CB-839) in combination with nivolumab in patients with metastatic melanoma, renal cell carcinoma, and non-small-cell lung cancerM A Gouda, M H Voss, H Tawbi, et al.
NPJ Breast Cancer|April 26, 2025
MUC1-C dependency in drug resistant HR+/HER2- breast cancer identifies a new target for antibody-drug conjugate treatmentAyako Nakashoji, Atrayee Bhattacharya, Hiroki Ozawa, et al.
Oncogene|February 22, 2007
The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272Y Minami, T Shimamura, K Shah, et al.
JAMA Network Open|October 18, 2022
Diagnostic Accuracy of a Bacterial and Viral Biomarker Point-of-Care Test in the Outpatient SettingNathan I Shapiro, Michael R Filbin, Peter C Hou, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 12, 2013
Co-clinical trials demonstrate superiority of crizotinib to chemotherapy in ALK-rearranged non-small cell lung cancer and predict strategies to overcome resistanceZhao Chen, Esra Akbay, Oliver Mikse, et al.
Acta Physiologica (Oxford, England)|March 22, 2021
The Na/K-ATPase α1/Src interaction regulates metabolic reserve and Western diet intoleranceLaura C Kutz, Xiaoyu Cui, Jeffrey X Xie, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 29, 2012
A phase I first-in-human trial of bardoxolone methyl in patients with advanced solid tumors and lymphomasDavid S Hong, Razelle Kurzrock, Jeffrey G Supko, et al.
Journal of the American Society of Nephrology : JASN|April 14, 2006
Non-contrast-enhanced computerized tomography and analgesic-related kidney disease: report of the national analgesic nephropathy studyWilliam L Henrich, Richard L Clark, Judith P Kelly, et al.
Molecular Cancer Research : MCR|November 29, 2022
MUC1-C Dictates PBRM1-Mediated Chronic Induction of Interferon Signaling, DNA Damage Resistance, and Immunosuppression in Triple-Negative Breast CancerNami Yamashita, Yoshihiro Morimoto, Atsushi Fushimi, et al.
Cancer|April 26, 2017
Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus: Results of a phase 2 studyEytan Ben-Ami, Constance M Barysauskas, Sarah Solomon, et al.
Pageof 118